Physician profile
Ayan R Patel
NPI 1720013865
$63,608.50
in general payments reported to CMS, 2019-2025
6 companies · $8,887 in 2025
The $8,887 reported for 2025 was more than what 94% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,420 · 2020: $12K · 2021: $13K · 2022: $16K · 2023: $6,280 · 2024: $1,611 · 2025: $8,887.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $16K · Food and Beverage: $441 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $47.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $16,289.32 |
| Food and Beverage | $440.88 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $47.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $46,011.00 | 2019-2023 | Vns - Vitaria |
| Pfizer INC. | $11,890.18 | 2019-2025 | |
| Bridgebio Pharma, INC. | $2,763.00 | 2025 | Attruby |
| Astrazeneca Pharmaceuticals LP | $1,611.00 | 2024 | |
| Genzyme Corporation | $1,333.32 | 2023-2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ayan Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.